Country for PR: United States
Contributor: PR Newswire New York
Wednesday, December 21 2022 - 12:00
PeproMene Bio, Inc. Announced Complete Response of The First Patient Treated in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope
IRVINE, Calif., Dec. 21, 2022 /PRNewswire-AsiaNet/ --

PeproMene Bio, Inc., a clinical-stage biotech company developing novel 
therapies to treat cancers and immune disorders, today announced that the first 
patient treated in its phase 1 relapsed or refractory B-cell Non-Hodgkin 
Lymphoma (r/r B-NHL) clinical trial of PMB-CT01 (BAFFR-CAR T Cells) has reached 
Complete Response at 1-month post treatment. The trial is taking place at City 
of Hope ( 
), one of the largest cancer research and treatment organizations in the United 

Logo - 

During the first month of treatment, the patient only experienced low grade 
treatment emergent toxicities, including grade 1 cytokine release syndrome 
("CRS") with full recovery and no immune effector cell-associated neurotoxicity 
syndrome ("ICANS"). "This mantle cell lymphoma patient has been refractory to 
several prior lines of treatment including chemoimmunotherapy, BTK inhibitor, 
Venetoclax, and CD19-CAR T therapy.  We are pleased to see a deep complete 
remission which is minimal residual disease negative," said Elizabeth Budde ( 
), M.D., Ph.D., City of Hope associate professor, Division of Lymphoma, 
Department of Hematology & Hematopoietic Cell Transplantation and the principal 
investigator of this single-center, dose escalation trial (NCT05370430).

"Despite high initial efficacy of CD19-CAR T cell treatment for B-cell lymphoma 
and leukemia, there is a significant unmet medical need for those patients who 
unfortunately relapse," said Larry W. Kwak ( 
), M.D., Ph.D., vice president and deputy director of City of Hope's 
Comprehensive Cancer Center and PeproMene's scientific founder and compensated 
chair of its  Scientific Advisory Board. Kwak has an equity interest in 
PeproMene. "As BAFF-R is a novel tumor target for B-cell malignancies, I am 
hoping BAFFR-CAR T therapy will offer a clinically meaningful, new option for 
those patients."

"The acceptable safety profile and early complete response of our first B-NHL 
patient treated PMB-CT01 is an unprecedented milestone in the development and 
evaluation of PMB-CT01. These initial clinical outcomes are supported by City 
of Hope preclinical research data published in Science Translational Medicine 
in 2019, which showed that PMB-CT01 (BAFFR-CAR T Cells) can overcome CD19 
antigen loss in B-cell malignancies," said Hazel Cheng, Ph.D., COO of PeproMene.

About PMB-CT01
PMB-CT01 is a first-in-class BAFFR-targeted, autologous CAR T cell therapy.  
BAFF-R (B Cell Activating Factor Receptor), a tumor necrosis factor (TNF) 
receptor superfamily member, is the main receptor for BAFF expressing almost 
exclusively on B cells. Since BAFF-R signaling promotes normal B-cell 
proliferation and appears to be required for B-cell survival, it is unlikely 
tumor cells could escape immune responses via loss of BAFF-R antigen. This 
unique characteristic makes BAFF-R CAR T therapy a great potential treatment of 
B cell malignancies.  BAFF-R CAR-T was constructed using the anti-BAFF-R scFv 
(single-chain fragment variable) antibodies with the 2nd generation signaling 
domains containing CD3ζ and 4-1BB. Our research has found that BAFFR-CAR T 
cells kill human lymphomas and leukemias in vitro as well as in animal models. 
PeproMene has licensed intellectual property relating to PMB-CT01, from City of 

About PeproMene
PeproMene is a clinical-stage biotech company in Irvine, California developing 
novel therapies to treat cancers and immune disorders. PeproMene's lead 
candidate, PMB-CT01 (BAFFR-CAR T Cells) is currently being investigated to 
treat relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL; 
NCT04690595) and B-cell Non-Hodgkin's lymphoma (B-NHL; NCT05370430) in phase 1 
clinical trials.  PeproMene is also developing BAFFR Bispecific T Cell Engager 
and BAFFR-CAR NK cells. For more information, contact Hazel Cheng, Ph.D. of 
PeproMene Bio Inc. at or visit

SOURCE: PeproMene Bio, Inc.